Anteris Technologies Reports Positive 30-Day Outcomes for Medium-Size DurAVR THV in EMBARK Study

Anteris Technologies reported positive 30-day results for the medium-size DurAVR transcatheter heart valve in 22 EMBARK study patients with severe aortic stenosis and medium aortic annuli. The valve’s effective orifice area averaged 2.64 ± 0.19 cm², up from a baseline of 0.8 ± 0.2 cm², while the mean pressure gradient was 6.17 ± 1.40 mmHg. No valve-related deaths, moderate or severe paravalvular leaks, or prosthesis-patient mismatch were reported at 30 days; the article gave no financial results or stock-price impact.